Alyeska Investment Group
PRNB

Alyeska Investment Group’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Alyeska Investment Group’s Portfolio PRNB Stock Details PRNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100,000
Closed -$2.92M – 511
2018
Q3 		$2.92M Buy
+100,000
New +$2.82M 0.03% 274

Other funds holding PRNB

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
MMPI
Morgenthaler Management Partners IX Portola Valley, California $22.6M AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Alyeska Investment Group's PRNB Position: Q4 2018 in Review

Alyeska Investment Group sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q4 2018, closing a stake of 100,000 shares — an estimated $2.92M sold.

Alyeska Investment Group first reported a position in PRNB in Q3 2018 and held it in 1 quarter. The position peaked at $2.92M in Q3 2018. 53 funds tracked by Wall St. Rank hold PRNB as of Q4 2018.

  • Alyeska Investment Group reported no remaining Principia Biopharma Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 100,000 Principia Biopharma Inc. Common Stock shares in Q4 2018, an estimated $2.92M.
  • Alyeska Investment Group first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Alyeska Investment Group's Principia Biopharma Inc. Common Stock position peaked at $2.92M in Q3 2018.
  • 53 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q4 2018.

Based on Alyeska Investment Group's 13F filing for Q4 2018, filed 14 Feb 2019.